NYSE:PFE

Pfizer Inc (PFE)

27.75
+0.03 (0.11%)
as of Sep 14, 2026, 5:42:20 pm Market Open.
583 watching
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
TOP PICK
Likes. Best product line and a good pipeline. AT a good price.
BUY
Cheap. Great pipeline. Low risk.
BUY
Should do well even in a recession. Good price.
TOP PICK
Prefers this and American Home over Lilly. Good product line.
TOP PICK
Aging population. Nine new drugs coming out in the next 3 years. Great pipeline. 40% growth.
PAST TOP PICK
(Was a top pick on Apr 12/01 even) Still a big fan. Good sector to be in. Strong pipeline. Reports are good. Good price.
BUY
Have a tremendous pipeline for new drugs.
BUY
Good short/long term growth potential. Great pipeline.
DON'T BUY
Suspicious of large cap drug companies. High risk industry.
BUY ON WEAKNESS
A little high now. Buy below $40.
TOP PICK
(Was a top pick on Jan 8/01 up 2%) Prefers over Merck. Less patent expiries. In a good position with good pipeline.
BUY
Likes both Pfizer and Merck in pharmaceuticals.
DON'T BUY
Caution. At its FMV.
TOP PICK
Least amount of patent expiry. Have some good new product launches. Good pipeline.
BUY
Always expensive, but a good pipeline. Long term.
Showing 856 to 870 of 890 entries